Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Covington
Federal Trade Commission
Daiichi Sankyo
Queensland Health
Argus Health
Cipla
Teva
Express Scripts

Generated: July 21, 2018

DrugPatentWatch Database Preview

VELPHORO Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Velphoro patents expire, and when can generic versions of Velphoro launch?

Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-two patent family members in thirty-eight countries.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sucroferric oxyhydroxide profile page.
Summary for VELPHORO
International Patents:72
US Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 1
Clinical Trials: 2
DailyMed Link:VELPHORO at DailyMed
Drug patent expirations by year for VELPHORO
Generic Entry Opportunity Date for VELPHORO
Generic Entry Date for VELPHORO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage::
TABLET, CHEWABLE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VELPHORO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vifor Fresenius VELPHORO sucroferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Vifor Fresenius VELPHORO sucroferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for VELPHORO

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015003 Lithuania ➤ Sign Up PRODUCT NAME: POLICIKLINES GELEZIES (III) OKSIHIDROKSIDO, SACHAROZES IR KRAKMOLU MISINYS; REGISTRATION NO/DATE: EU/1/14/943/001 - EU/1/14/943/004 20140826
5 Finland ➤ Sign Up
00710 Netherlands ➤ Sign Up PRODUCT NAME: MENGSEL VAN POLYNUCLEAIRE IJZER (III)-OXYHYDROXIDE, SUCROSE EN ZETMEEL; REGISTRATION NO/DATE: EU/1/14/943 20140826
C/GB14/087 United Kingdom ➤ Sign Up PRODUCT NAME: MIXTURE OF POLYNUCLEAR IRON(III)OXYHYDROXIDE, SUCROSE AND STARCHES; REGISTERED: UK EU/1/14/943/001 20140828; UK EU/1/14/943/002 20140828; UK EU/1/14/943/003 20140828; UK EU/1/14/943/004 20140828
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Express Scripts
Chinese Patent Office
Mallinckrodt
Baxter
Cerilliant
Merck
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.